December 1, 2017

Melinta Therapeutics pays $270M for infectious disease drugs

New Haven's Melinta Therapeutics Inc., which is developing antibiotics to treat serious bacterial infections, said Wednesday it will pay $270 million to acquire the infectious disease business from a New Jersey-based biopharmaceutical company, bolstering its antibiotic portfolio and commercial team.

Melinta's acquisition from The Medicines Co. includes the company's recently approved and launched drug Vabomere, which treats adult patients with complicated urinary tract infections. Melinta will also acquire the drugs Orbactiv, which treats acute bacterial skin and skin structure infections (ABSSI), and Minocin IV, which treats hospital-related infections.

The acquisition, which is being paid for in cash and stock, is expected to close in the first quarter of 2018.

Melinta said the acquisition, combined with the Baxdela antibiotic it is preparing to launch commercially in first quarter 2018 to treat bacterial skin infections, gives it a valuable portfolio of four complementary antibiotics and bolsters its commercial team with experienced anti-infective professionals from The Medicines Co.

Peak sales potential of the four-drug portfolio after the deal closes will exceed $1 billion, Melinta said.

Free E-Newsletter

Sign up now for our New Haven Biz
e-newsletter! Click Here

Subscribe to print for free

Premier issue coming in October. Click here to subscribe

Copyright 2018 New England Business Media